Literature DB >> 10556212

Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.

R Childs1, E Clave, N Contentin, D Jayasekera, N Hensel, S Leitman, E J Read, C Carter, E Bahceci, N S Young, A J Barrett.   

Abstract

Nonmyeloablative allogeneic stem cell transplantation has recently been explored as a safer alternative to conventional high-dose transplant regimens. Although a high incidence of mixed chimerism after nonmyeloablative procedures has been reported, the exact kinetics of engrafting donor cells in specific cellular lineages has yet to be defined. We investigated lineage-specific chimerism in 15 patients receiving an allogeneic peripheral blood stem cell (PBSC) transplant from an HLA-identical (n = 14) or a 5/6 antigen-matched sibling donor after a preparative regimen of cyclophosphamide and fludarabine. Donor chimerism was assessed weekly in T lymphocytes and myeloid cells by polymerase chain reaction (PCR) of minisatellite regions. Eight patients survived between 121 to 409 days after transplant. Ten of 14 patients surviving more than 30 days (71.4%) had delayed disease regression consistent with a graft-versus-malignancy (GVM) effect. One patient rejected the transplant with subsequent recovery of autologous hematopoiesis. Hematological recovery was rapid (median, 11 days to >/=500 neutrophils/microL) and was initially predominantly recipient in origin. Donor myeloid chimerism gradually supplanted recipient hematopoiesis and became fully donor in all survivors by 200 days after transplantation. In contrast, T-cell engraftment was more rapid, with full chimerism in 7 patients by day 30 and in 6 further patients by day 200 after cyclosporine withdrawal and donor lymphocyte infusion. Full donor T-cell engraftment preceded donor myeloid engraftment, acute graft-versus-host disease, and disease regression, consistent with a requirement for 100% donor T-cell chimerism for full expression of the alloresponse. These results emphasize the importance of lineage-specific chimerism analysis to successfully manipulate engraftment after nonmyeloablative allogeneic PBSC transplantation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556212

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

Review 1.  Tolerance induction for solid organ grafts with donor-derived hematopoietic reconstitution.

Authors:  K L Gandy
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 2.  NKT cells, Treg, and their interactions in bone marrow transplantation.

Authors:  Holbrook E Kohrt; Asha B Pillai; Robert Lowsky; Samuel Strober
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

3.  In mixed hematopoietic chimerism, the donor red cells win.

Authors:  Matthew M Hsieh; Catherine J Wu; John F Tisdale
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

4.  Successful nonmyeloablative bone marrow transplantation for leukocyte adhesion deficiency type I from an unrelated donor.

Authors:  Masahiro Tokunaga; Koichi Miyamura; Haruhiko Ohashi; Naruhiko Ishiwada; Seitaro Terakura; Miyoko Ikeguchi; Yachiyo Kuwatsuka; Yoshihiro Inamoto; Taku Oba; Shigeru Tsuchiya; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 5.  Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care.

Authors:  Razvan Diaconescu; Rainer Storb
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-28       Impact factor: 4.553

6.  Isolation and therapeutic potential of human haemopoietic stem cells.

Authors:  Andrew D Clark; Heather G Jørgensen; Joanne Mountford; Tessa L Holyoake
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

7.  Persistence of recipient human leucocyte antigen (HLA) antibodies and production of donor HLA antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation.

Authors:  Ross M Fasano; Ewelina Mamcarz; Sharon Adams; Theresa Donohue Jerussi; Kyoko Sugimoto; Xin Tian; Willy A Flegel; Richard W Childs
Journal:  Br J Haematol       Date:  2014-04-18       Impact factor: 6.998

Review 8.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

9.  Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.

Authors:  Yoshiyuki Takahashi; Nanae Harashima; Sachiko Kajigaya; Hisayuki Yokoyama; Elena Cherkasova; J Philip McCoy; Ken-Ichi Hanada; Othon Mena; Roger Kurlander; Abdul Tawab; Tawab Abdul; Ramaprasad Srinivasan; Andreas Lundqvist; Elizabeth Malinzak; Nancy Geller; Michael I Lerman; Richard W Childs
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

Review 10.  Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.